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TREATMENT OF CHRONIC HEART FAILURE 
(CHF): IMPROVING SURVIVAL BUT NOT 
HEALTH-RELATED QUALITY OF LIFE (HRQL)
Chassany O, Mahe I, Duracinsky M
Therapeutic Research Unit, Lariboisiere Hospital, Paris, France
OBJECTIVE: Treatments such as ACE inhibitors and
beta-blockers reduce mortality in CHF. Demonstration
of a parallel improvement of HRQL would appear of
good added value. METHOD: A critical appraisal of
published controlled trials used the guidance document
and the checklist developed by ERIQA. RESULTS: Al-
though a reduction of mortality and NYHA score was
demonstrated in a few large studies, none was able to
show a clear and unbiased HRQL improvement vs. pla-
cebo. Several major issues that would increase the confi-
dence in the results are not presented or missing: hypoth-
eses of changes in HRQL scores and power estimation;
justification of the choice of questionnaires (e.g. 6 ques-
tionnaires were used in a trial and presented as HRQL,
some of them being a dyspnoea score or a global evalua-
tion of change, with no explanation whether they were
covering different concepts, and without selecting the
most important questionnaire for the primary statistical
analysis); validation data (e.g. a trial used 14 subscales
taken from 3 different validated questionnaires. Is the re-
sultant questionnaire still valid?); statistical analysis plan;
description and imputation of missing data; statement
that the analysis is in intent to treat. In the majority of
trials, small differences were observed for a few subscales
among many, or only at some assessments over time.
When the difference reaches statistical significance, it is
only because of the large sample, but it has no clinical
signification. Even for the physical subscale which may
be of importance in CHF, small non significant effect
sizes are observed. Some explanations have been proposed
for these results: non severe patients included, questionnaire
not reliable or responsive. CONCLUSION: There is con-
cern to conclude that despite attempts of publications
and general reviews to enhance the modest results, there
is no definite demonstration that HRQL is improved by
treatment which reduces mortality in CHF.
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SAVINGS ACHIEVED IN AN HMO SPONSORED 
PRIMARY CARE BASED DISEASE MANAGEMENT 
AND CASE MANAGEMENT INITIATIVE
Fisher FJ1, Sidorov J2, Fox G2, Girolami S2, Dobeck L2, 
Donmoyer C2, Riehl P2, Shull R2, Wolke O3
1Schellen & Partners, Düsseldorf, Germany; 2Care Coordination 
Department, Geisinger Health Plan, Danville PA, USA; 
3Schellen and Partners, Danville, PA, USA
OBJECTIVE: To describe the cost savings achieved in
HMO sponsored primary care-based case management
and disease management programs in asthma, diabetes
mellitus and congestive heart failure (CHF). METHODS:
Continuously enrolled participants’ total per member per
month (PMPM) charges for medical services one year
prior and one year after entry into HMO sponsored case
management and disease management programs were
compared during fiscal year January 1, 1998 to March
31, 2000. The HMO sponsored programs recruited pa-
tients in the primary care setting and relied on clinical
guidelines and HMO employed patient education nurses
and case management nurses. This initiative is based in
55 primary care sites serving 295,000 insureds across
northeastern and central Pennsylvania in the United States.
RESULTS: 327 patients with asthma had baseline PMPM
of $311, which dropped to $274 PMPM after entry. In
diabetes, 3,953 patients had a baseline PMPM of $468
that dropped to $434. The baseline PMPM dropped from
$1,748 to $1,402 for 870 patients with CHF. For 965
patients receiving case management, the baseline PMPM
was $1,074 and it dropped to $887. Total reductions in
claims over one year for each program was $112,524,
$1,264,052, $2,587,068 and $1,516,784, respectively
with a total reduction in health care claims of $5,480,428.
CONCLUSION: While these claims data may be limited
by a lack of statistical significance and by regression to
the mean, they suggest that case management and disease
management programs in asthma, diabetes and conges-
tive heart failure may be able to achieve significant finan-
cial savings compared to baseline levels of utilization.
PCV29
SUPPORTING IMPLEMENTATION OF 
PRESCRIPTION GUIDELINES IN MEDICAL 
WARDS: A RANDOMIZED TRIAL
Fontaine A, Vinceneux P, Fiessinger JN, Bergmann JF, Dhote 
R, Cohen P
Collégiale de Médecine Interne, Assistance Publique-Hôpitaux 
de Paris, Paris, France
OBJECTIVE: To evaluate the acceptability and effective-
ness of a “guided prescription” form implementing lo-
cally developed guidelines for preventive anticoagulation.
METHODS: Thirty internal medicine wards were ran-
domly assigned to either intervention (I) or control (C)
group. I-group physicians were asked to use the guided
prescription form whenever they considered prescribing
preventive anticoagulation over a 2-month period. One-
day surveys of all patients hospitalized in I and C wards
were conducted before and after this intervention period.
Physicians were also asked to rate independently whether
preventive anticoagulation was required for a series of
isolated or combined risk factors (1–9 scale), and to as-
sess several attributes of the form (4-degree Likert scale).
RESULTS: Of 313 completed prescription forms col-
lected from I wards during the intervention period, 262
(84%) followed recommendations; an explicit “other”
option was used for 36 additional patients (12%). Before
and after surveys showed an overall decrease from 41%
(146/358) to 33% (121/365) (95% CI: 11% to 4%)
in the prevalence of preventive anticoagulation in I
wards, while prescriptions remained stationary at 38%
(154/402 and 134/352) in C wards. While scores as-
Abstracts 321
signed to risk factors that did not justify preventing anti-
coagulation according to the guideline tended to decrease
in both groups, this was more marked in the I group. Al-
most all physicians in both groups agreed that using this
form would help improving preventive anticoagulant pre-
scriptions. Nevertheless, 8/45 in the C group and 15/46
in the I group thought that it might hinder prescribing
treatments that could benefit patients. CONCLUSION:
Further analyses are underway to confirm that changes
observed in I group prescriptions reflect improved agree-
ment with the guidelines, and to assess variations across
wards and/or for different risk factors or combinations,
reflecting possible differences in supervision by senior
physicians, or demonstrating the need to improve the
documentation of specific recommendations.
INFECTIOUS DISEASE 
PID1
ASSOCIATED OUTCOMES OF INFLUENZA-LIKE-
ILLNESS AND CLINICAL INFLUENZA IN ITALY
Costa B, Arpinelli F, Bamfi F
Medical Department, Glaxo Wellcome S.p.A., Verona, Italy
OBJECTIVES: to estimate the natural history of influ-
enza and the associated resource utilization and General
Practitioner (GPs) workload in the Italian general popu-
lation. METHODS: during a three-month winter epi-
demic period, 199 GPs from one Northern and one
Southern Italian region reported daily the number of vis-
its because of Influenza-like-illness (ILI), Clinical influ-
enza (CI) and any other cause. Furthermore, the first 10
cases of CI in each month of the three-month period (a
total of 30 cases per GP), were carefully recorded and fol-
lowed up. RESULTS: about 200,000 visits were per-
formed by 199 GPs. ILI and CI accounted for 13.8% and
8.3% of all visits respectively. Six thousand and fifty
seven cases of CI were collected and evaluated for out-
comes. In our sample, 20% of patients (pts) were at risk
because of age (	65 years) or concurrent conditions. Al-
most all pts received at least one prescription for symp-
tomatic drugs, and 36% received antibiotics. Complica-
tions (primarily upper and lower respiratory tract bacterial
infections) affected 35% of pts. At risk pts had significantly
higher complication rate (OR  2.89; 95%C.I. 2.44–3.41),
and required more exams and hospitalizations than other
pts, accounting for most of direct costs associated with
CI. Pts with CI had an average of 5 days of absence from
work or school. CONCLUSIONS: influenza is associated
with significant morbidity in general and at risk popula-
tion, considerable working days lost and sizeable excess
workload for GPs.
PID2
PHARMACOECONOMIC EVALUATION OF 
IMMUNOPROPHYLAXIS FOR RESPIRATORY 
SYNCYTIAL VIRUS (RSV) INFECTION IN
HIGH-RISK INFANTS
Doshi J, Kamal-Bahl S
Pharmacy Practice and Sciences, University of Maryland, 
Baltimore, MD, USA
Respiratory syncytial virus (RSV), the leading cause of
lower respiratory tract infection in children, results in an es-
timated 90,000 hospitalizations and 4,500 deaths each year
in the United States. Children with underlying bronchopul-
monary dysplasia, prematurity or immunodeficiency are
known to be at high-risk for severe RSV illness. OBJEC-
TIVE: To evaluate research addressing the pharmaco-
economics of RSV immunoglobulin (RSV-IG) and palivi-
zumab, the only two available agents, to prevent RSV
infection among high-risk infants. METHODS: Studies in
English were identified from Medline (1993 to 2000) using
search terms like RSV-IG, palivizumab, costs, cost-effective-
ness. Additional studies were collected by searching bibliog-
raphies of identified articles and contacting study authors
and other experts. Data was abstracted from each study us-
ing a standardized reporting form. RESULTS: Cost per hos-
pitalization averted was the primary outcome measure
across most studies. Cost-effectiveness estimates of RSV-IG
have ranged from $3,800 to $8,800 per respiratory related
hospitalization prevented, to $24,000 per year of life saved,
to $102,608 to prevent hospitalization of a 3.3 kg infant.
Economic evaluation of palivizumab also indicate varied es-
timates ranging from expected savings of 39,107 per in-
fant to costs of $72,712 per hospitalization prevented. Two
recent studies compared both palivizumab and RSV-IG.
The cost-effectiveness of both agents varied widely among
different subgroups of premature infants based on their risk
of RSV hospitalization defined by gestational age and dura-
tion of respiratory support. Some studies used assumptions
about reduced mortality and morbidity that have not been
shown in the clinical trials. Also cost-effective models utiliz-
ing RSV hospitalization rates from clinical trials reported
less favorable results. CONCLUSION: Both RSV-IG and
palivizumab are very costly interventions. Inconsistent data
exists to conclude which is more cost-effective. In the ab-
sence of alternatives to the two agents, further research
needs to be performed to determine the overall cost-effec-
tiveness of immunoprophylaxis for RSV infection.
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COST-EFFECTIVENESS OF HEPATITIS B 
VACCINATION IN THE NETHERLANDS
De Wit GA1, Kretzschmar MEE2, Struijs JN1, Smits LJM2, 
Postma MJ3, van de Laar MJW2, Jager JC1
1Department of Health Services Research, National Institute of 
Public Health and the Environment, Bilthoven, The 
Netherlands; 2Department of Infectious Diseases Epidemiology, 
National Institute of Public Health and the Environment, 
Bilthoven, The Netherlands; 3Groningen University Institute for 
Drug Exploration, Groningen, The Netherlands
